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Objectives. We sought to examine endothelial responses to
L-arginine in three groups with isolated risk factors: hypercholes-
terolemia, smoking and insulin-dependent diabetes mellitus
(IDDM).
Background. Endothelial dysfunction occurs early in athero-
sclerosis, predating clinical disease. We hypothesized that the
nature of endothelial injury associated with individual cardiovas-
cular risk factors might be different and that this might affect the
response to L-arginine, the substrate for endothelial nitric oxide
synthase.
Methods. We studied the effects of intravenous L-arginine on
brachial artery flow-mediated dilation (FMD) and glyceryl trini-
trate (GTN)–mediated dilation in 36 young subjects (18 to 40
years old) without clinical atherosclerosis: 9 each of normal
control subjects, hypercholesterolemic subjects, cigarette smokers
and subjects with IDDM.
Results. Baseline FMD was significantly impaired in hypercho-
lesterolemic subjects (mean 6 SD 1.7 6 2.3%), smokers (1.6 6
1.8%) and diabetic subjects (1.8 6 1.5%) compared with that in
control subjects (6.9 6 3.3%, p 5 0.001). The response to GTN was
not significantly different between the subjects with risk factors
and control subjects, apart from those with IDDM, in whom it was
significantly impaired (p 5 0.026). After infusion of L-arginine,
there was no change in FMD in control or diabetic subjects. In
hypercholesterolemic subjects and smokers, FMD improved from
1.9 6 1.9% to 4.1 6 2.1% (p 5 0.01) and from 2.0 6 1.71% to 3.1 6
2.5% (p 5 0.02), respectively.
Conclusions. FMD was impaired in all three risk factor groups;
however, they responded differently to L-arginine, FMD being
improved in hypercholesterolemic subjects and smokers but un-
changed in diabetic subjects. These results indicate differing
underlying pathophysiologies that may facilitate the design of
treatment strategies for subjects with different risk factors.
(J Am Coll Cardiol 1998;32:110–6)
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Hypercholesterolemia, cigarette smoking and insulin-dependent
diabetes mellitus (IDDM) are established risk factors for
atherosclerosis and premature cardiovascular disease (1–4)
and are known to impair endothelial function, a key factor in
early atherogenesis (5–8). Constitutive release of nitric oxide
(NO) is a hallmark of healthy endothelium (9). It not only
causes vasodilation but also has antiatherogenic effects, inhib-
iting interactions between platelets, leucocytes and the vessel
wall and inhibiting smooth muscle proliferation (10). Loss of
this function may therefore be important in the development
of early vessel wall damage, leading eventually to atheroscle-
rotic plaque formation (11). The mechanisms by which these
three apparently disparate risk factors result in vascular dam-
age remain incompletely understood. Decreased bioavailability
of L-arginine may be a common factor, and the administration
of L-arginine, the substrate for NO synthase, has been shown to
improve endothelial function in hypercholesterolemia (12–15).
However, there are conflicting results as to the effects of
L-arginine in animal models of diabetes (16,17), and its impact
in vivo in either IDDM or smoking has not been reported.
We therefore studied the effects of intravenous L-arginine
on endothelial-dependent dilation in the conduit arteries of
young subjects with hypercholesterolemia or IDDM or who
smoked and compared the responses with those in control
subjects without risk factors. The findings showed a heteroge-
neity of response, with improvement in flow-mediated dilation
(FMD) in hypercholesterolemic subjects and smokers but no
effect in subjects with IDDM, suggesting that the nature of
early vascular injury differs between these three risk factor
groups. This finding may need to be taken into account when
designing therapeutic strategies aimed at the reversal or pre-
vention of early arterial damage.
Methods
Subjects. Twenty-seven subjects were selected for study if
they were #40 years old and had no clinical vascular disease
but had one of three major cardiovascular risk factors: hyper-
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cholesterolemia, cigarette smoking or IDDM. None had hy-
pertension or a family history of premature vascular disease or
were taking vasoactive or lipid-lowering medication. Hyper-
cholesterolemic subjects (total plasma cholesterol $5.7 mmol/
liter) were selected from a database. Current cigarette smokers
were studied if they had smoked #2 pack-years (1 pack-year 5
20 cigarettes/day for 1 year). Subjects with IDDM for .2 years
had all presented with ketoacidosis at time of diagnosis and
were recruited from diabetic clinics. None had clinical evi-
dence of retinopathy or microalbuminuria (urinary albumin/
creatinine ratios ,0.01). Findings were compared with those of
nine age- and gender-matched volunteers recruited from the
hospital staff in whom the above risk factors had been ex-
cluded. All subjects gave written informed consent, and ethical
approval was granted by the local ethics committee.
Study protocol. Vascular responses in the brachial artery
were studied in each subject on two separate days (3 to 10 days
apart, with no therapeutic interventions between) during which
either L-arginine (Martindale Pharmaceuticals UK) (0.1 g/kg
body weight in 100 ml of 0.9% saline) or 100 ml 0.9% saline
was administered intravenously over 20 min. The order of
administration was randomized in double-blind fashion, and
the same operator (A.E.D.) performed all ultrasound scans.
Baseline blood samples were taken at rest, and L-arginine
levels were also measured immediately and 20 min after
infusions. Total plasma cholesterol was measured using the
cholesterol C-system high performance CHOD-PAP method,
and plasma triglycerides were measured using the GPO-PAP
high performance enzymatic colorimetric test (both
Boehringer-Mannheim GmbH, Diagnostica). High density li-
poprotein (HDL) cholesterol was measured after precipitation
of apoprotein B-containing lipoproteins, and low density li-
poprotein (LDL) cholesterol was calculated according to the
Friedwald formula (18). Plasma L-arginine was measured by
ion exchange separation and reaction with ninhydrin (Pharma-
cia Alpha Plus amino acid analyzer). Glycosylated hemoglobin
(HbA1) (Rapid EP system, Helena Laboratories) and urinary
microalbumin were measured in the diabetic group. Noninva-
sive high resolution brachial artery ultrasound scans were
performed before and after each infusion, using a modification
of a technique that we have described previously (19). Arterial
endothelial and smooth muscle function were assessed by
examining brachial artery responses to endothelial dependent
(flow mediated) (20) and independent (glyceryl trinitrate
[GTN]–mediated) stimuli. A baseline scan was performed
after 15 min of supine rest. A pneumatic tourniquet was
inflated around the forearm for 4.5 min to a pressure of
300 mm Hg and then rapidly deflated, leading to reactive
hyperemia in the hand and increased brachial artery blood
flow. Brachial artery diameter and wall motion were recorded
during the 55 to 65 s after cuff deflation using a high resolution
(diameter evolution ,3mm) A-mode echo tracking device
(AMA, The Netherlands) and a 7-MHz linear array transducer
with a stereotactic clamp and a standard Acuson 128XP10
system (Acuson). B- and M-mode images were obtained, and
the exact position of each processed radio frequency peak
corresponding to the vessel wall lumen interface, tagged using
electronic trackers, was determined by an interpolation tech-
nique. Calculation of end-diastolic brachial artery diameter
was performed automatically. At each stage of the experiment,
continuous wall motion was recorded for 5 s, allowing the
mean diameter of 4 to 10 cardiac cycles to be taken. Volumet-
ric blood flow was calculated using pulsed-wave Doppler with
a 1.5-mm sampling gate at an angle of 70° to the longitudinal
axis, in the center of the artery, both at rest and at maximal
flow during the first 15 s after tourniquet release, and images
and velocity measurements were obtained simultaneously.
Reactive hyperemia was expressed as the percent increase in
blood flow. Because Doppler measurements were taken from
the center of the vessel, calculations of flow may be overesti-
mated; but because reactive hyperemia was calculated as a
ratio of baseline and post–cuff deflation flows, relative values
are accurate. After L-arginine or saline infusion, further base-
line and reactive hyperemia measurements were made. After a
10-min recovery period, brachial artery response to GTN was
measured.
Statistics. Descriptive data are expressed as mean value 6
SD, and statistical significance was inferred at a p value ,0.05.
Baseline FMD (Fig. 1) was calculated as the mean of the
pre–L-arginine and pre–saline infusion FMD values, measured
on the two separate days. Comparisons within individual
groups were made by paired t tests. To compare responses
between groups a two-way repeated measures analysis of
variance (ANOVA) was used, and appropriate adjustments
were made for multiple comparisons. For the whole group, the
relation between the dependent variable FMD, change in
FMD after L-arginine or placebo and response to GTN and the
independent variables age; gender; vessel size; presence or
absence of diabetes; triglycerides; and total, HDL and LDL
cholesterol was explored using simple univariate analysis, and
then the same variables were entered into a stepwise multivar-
iate linear regression analysis. Within the diabetic and smoking
groups, similar analyses were performed, introducing duration
of diabetes and HbA1 or total number of pack-years as
independent variables.
Abbreviations and Acronyms
ADMA 5 asymmetric dimethyl arginine
ANOVA 5 analysis of variance
FMD 5 flow-mediated dilation
GTN 5 glyceryl trinitrate
HbA1 5 glycosylated hemoglobin
HDL 5 high density lipoprotein
IDDM 5 insulin-dependent diabetes mellitus
LDL 5 low density lipoprotein
NO 5 nitric oxide
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Results
Subject characteristics (Table 1). There were no signifi-
cant differences in age, gender or baseline heart rate and blood
pressure between the groups or in lipid profile between the
control subjects, smokers and diabetic subjects. Total plasma
and LDL cholesterol were higher (p , 0.0001), and HDL
cholesterol lower (p 5 0.02) in the hypercholesterolemic group
than in the control group. The mean number of pack-years
smoked by the smoker group was 10 6 6.6 (range 2 to 20). In
the diabetic group, mean age at diagnosis was 15.1 6 8.9 years
(range 5 to 32), and mean duration of diabetes was 14.9 6 7.4
years (range 3 to 29). Mean glycosylated hemoglobin levels
were 10.8 6 2.5% (range 8.1% to 14.4%). Venous blood
glucose in all subjects was between 3 and 10 mmol/liter at the
time of each scan. Plasma L-arginine rose 25-fold from a mean
of 77 6 43.7 mmol/liter (range 47 to 212) to 1,992 6 1,052.6
(range 504 to 4,017) mmol/liter. There were no differences
between the groups in preinfusion and postinfusion plasma
L-arginine concentrations. No subject had side effects after the
L-arginine or placebo infusions; two complained of shortlived
headache after GTN.
Preinfusion vascular study. There were no significant dif-
ferences within any of the groups between pre–saline and
pre–L-arginine infusion FMD (Fig. 2), and mean rest vessel
size, blood flow and percent increase in blood flow during
reactive hyperemia did not differ significantly between the four
groups (data not shown), indicating both the reproducibility of
the technique and the stable physiologic status of the subjects.
Baseline FMD was significantly reduced in hypercholester-
olemic, smoking and diabetic subjects compared with that in
control subjects (p 5 0.001) (Fig. 1).
Postinfusion vascular studies (Fig. 2 and 3). After L-arginine
or saline infusions, there were no changes in heart rate, blood
pressure, rest vessel size, rest blood flow or reactive hyperemia,
indicating that the infusions had no effect on distal vascular
tone. FMD improved significantly after L-arginine infusion in
the hypercholesterolemic and smoking groups, from 1.9 6
1.9% to 4.1 6 2.1% (p 5 0.03) and from 2.0 6 1.71% to 3.1 6
2.5% (p 5 0.02), respectively. However, there was no signifi-
cant change in the control (6.9 6 3.3% to 6.7 6 3.3%, p 5
0.22) and diabetic (1.8 6 1.5% to 2.2 6 2.1%, p 5 0.28) groups.
On two-way repeated measures ANOVA, there were signifi-
cant differences in the response to L-arginine in the hypercho-
lesterolemic (p 5 0.001) and smoking (p 5 0.02) groups but
Table 1. Clinical Characteristics*
Control
Group
Hyperchol
Group
Smoker
Group
IDDM
Group*
Age (yr) 30 6 4.5 34 6 8.3 34 6 3.0 31 6 5.4
Range 25–40 18–40 26–35 23–40
Female/male 3/6 3/6 3/6 3/6
Baseline HR (beats/min) 67.2 6 13.3 67.8 6 7.6 63.4 6 7.6 77.8 6 10.1
Baseline SBP (mm Hg) 120.0 6 9.5 119.1 6 10.0 123.7 6 9.7 118.0 6 10.0
p value 0.83 0.37 0.64
Baseline DBP (mm Hg) 74.1 6 10.4 73.5 6 10.6 77.2 6 11.3 70.1 6 9.6
p value 0.90 0.51 0.36
Total plasma chol (mmol/liter) 4.47 6 0.87 6.80 6 0.85 5.01 6 0.76 4.89 6 1.04
p value , 0.0001 0.17 0.2
Plasma HDL chol (mmol/liter) 1.46 6 0.26 1.14 6 0.29 1.38 6 0.47 1.61 6 0.62
p value 0.02 0.67 0.5
Plasma LDL chol (mmol/liter) 2.55 6 0.79 4.87 6 0.75 2.94 6 0.71 2.97 6 0.68
p value , 0.0001 0.29 0.26
Plasma TGs (mmol/liter) 1.0 6 0.42 1.53 6 1.21 1.47 6 1.02 1.03 6 0.32
p value 0.26 0.25 0.87
*p values indicate comparison between control and study groups. Unless otherwise indicated, data presented are
mean value 6 SD or number of subjects. DBP 5 diastolic blood pressure; HDL chol 5 high density lipoprotein
cholesterol; HR 5 heart rate; IDDM 5 insulin-dependent diabetes mellitus; LDL chol 5 low density lipoprotein
cholesterol; SBP 5 systolic blood pressure; TGs 5 triglycerides.
Figure 1. FMD at baseline in the four subject groups. FMD (mean of
presaline and pre–L-arginine levels) was significantly lower in the
hypercholesterolemic, smoking and diabetic groups than in the control
group. Bold lines represent mean values.
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not in the diabetic group (p 5 0.9) compared to that in the
control group. There was no change in FMD or any significant
difference between the groups in response to saline infusion.
There were no significant differences in brachial artery dilation
in response to GTN between the control (23.1 6 7.3%) and
hypercholesterolemia or smoking groups (18.7 6 6.9%, p 5
0.09 and 20.1 6 9.9%, p 5 0.46, respectively). However, in the
diabetic group dilation in response to GTN was significantly
reduced compared with that in the control group (13.3 6 9.6%,
p 5 0.026). There was no significant difference in response to
GTN after L-arginine compared with that after saline infusion
in any of the groups.
Analysis of results revealed no “order effect” dependent on
whether the saline or L-arginine infusions were given first.
There were no significant relations between the three depen-
dent variables FMD, change in FMD after placebo and
response to GTN and age, vessel size, lipid profile or presence
or absence of diabetes for the whole group, or with HbA1,
duration and age at diagnosis of diabetes, total pack-years
smoked within groups. On univariate but not multivariate
analysis, change in FMD in response to L-arginine correlated
significantly and directly with total plasma cholesterol and
triglyceride levels (r 5 0.33, p 5 0.049 and r 5 0.36, p 5 0.032
respectively).
Discussion
The present study shows that young subjects with different
cardiovascular risk factors and impaired endothelial-
dependent relaxation have differing responses to L-arginine,
with FMD improving in hypercholesterolemic subjects and
smokers but not in subjects with IDDM, a new finding con-
tinuing our previous work. Thus, even at this early preclinical
stage of atherosclerosis, the effects of L-arginine are deter-
mined by the differing nature or extent of vascular damage
associated with cardiovascular risk factors, a finding that
should influence the development of strategies to reverse or
prevent early arterial damage.
FMD and the L-arginine/NO pathway. There is increasing
evidence that the endothelial L-arginine/NO pathway has a key
antiatherogenic role (10). The same cardiovascular risk factors
that are causally implicated in the development of clinical
atherosclerotic disease cause impairment of endothelium-
dependent dilation. This impairment has been demonstrated in
the coronary and peripheral microvascular circulations (5,21–
23) and in large conduit arteries using a high resolution
ultrasound technique (19,24–27). FMD measurements are
reproducible (28), blocked by NG-monomethyl-L-arginine
Figure 2. FMD responses to L-arginine and saline. There were no
significant changes in FMD after saline infusion in any subject group.
After L-arginine infusion, FMD improved significantly in the hyper-
cholesterolemic subjects (b) (p 5 0.01) and smokers (c) (p 5 0.02) but
was unchanged in the control (a) and diabetic groups (d). In hyper-
cholesterolemic subjects and smokers, the percent change in FMD was
significantly greater after L-arginine than saline infusion (p 5 0.03 and
p 5 0.02, respectively); there were no differences in percent change in
FMD in either the control or diabetic groups. There were no signifi-
cant differences between presaline and pre–L-arginine FMD values (p
values not shown). Bold lines represent mean value 6 SD.
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(LNMMA) (29) and correlate with those demonstrated inva-
sively in the coronary vasculature (30). Impairment of dilation
in response to flow represents a failure of endothelial-
dependent homeostasis but provides no information on the
nature of the vascular injury responsible. The reported bene-
ficial effects of L-arginine administration in vivo remain con-
troversial. The purposes of our present study were thus
twofold: 1) to describe the effects of L-arginine in conduit
arteries of young subjects; and 2) to use the response to
L-arginine to further characterize the vascular abnormalities
associated with three different risk factor groups. We therefore
identified young subjects who had a single powerful cardiovas-
cular risk factor and who were otherwise matched for age,
gender and other physical characteristics known to affect shear
stress–mediated endothelial function. The young age of the
study group avoided the confounding influence of increasing
age on FMD (31). The small size of the study group may have
also contributed to the lack of a relation between FMD and
age or vessel size (19). We previously showed (15) improve-
ment in FMD after dietary supplementation with L-arginine in
young hypercholesterolemic subjects, but the effects of this
approach in cigarette smokers and in patients with IDDM have
yet to be determined. The findings of this short-term study,
which resulted in transiently high circulating levels of
L-arginine, cannot be extrapolated directly to predict benefits
that might be expected from long-term therapy with lower
L-arginine concentrations. We did not set out to determine the
relative improvements that could be achieved and thus only
compared responses in the risk factor groups with those found
in the risk factor–free control group. Separate studies would be
required to determine whether the degree of response differs
between risk factor groups and whether similar improvements
can be achieved with long-term oral therapy.
Hypercholesterolemia. The differing responses to L-arginine
may either reflect differences in the pathogenesis of athero-
sclerosis between the three risk factor groups or differences in
the way each risk factor responds to L-arginine. Impaired
endothelial dependent dilation in hypercholesterolemia has
been the most extensively researched. Our findings are consis-
tent with previous studies showing that L-arginine improves
endothelial function in animals (13) and humans (12,14,15),
but the mechanisms of action of L-arginine are unclear.
L-Arginine is unlikely to act merely by increasing NO substrate
availability (32), and NOS may interact with intracellular
L-glutamine (33) and the endogenous competitive inhibitor
asymmetric dimethyl arginine (ADMA) (34). However, NO
production may be preserved or even increased in hypercho-
lesterolemia (35,36), so that impaired vascular responses may
be due to accelerated NO breakdown (37). Our study suggests
that L-arginine is acting neither as a direct vasodilator nor to
increase basal NO activity. We found that the magnitude of
response to L-arginine for the entire study group was directly
related to total plasma cholesterol and triglyceride levels,
suggesting that the detrimental endothelial effects of hyperlip-
idemia might be particularly amenable to reversal by
L-arginine.
Smoking. The importance of smoking as a primary risk
factor for coronary disease is likely to increase over the next
four decades, unless the rise in smoking among young people
can be reversed (38). Cigarette smoking increases oxidative
stress because of low circulating levels of antioxidants and
increased levels of oxygen-derived free radicals and lipid
peroxides that degrade NO (39,40), enhance monocyte adhe-
sion (41) and increase the susceptibility of LDL to oxidation.
Oxidized LDL exerts numerous cytotoxic and atherogenic
effects (42,43) as well as interfering with the L-arginine/NO
pathway by decreasing both L-arginine uptake and NO syn-
thase expression (44). The observation that antioxidant vita-
mins can both reduce smoking-induced lipid peroxidation and
endothelial dysfunction suggests a way forward in planning
therapeutic strategies (45,46). The present study purposefully
examined separate risk factors and showed that each can cause
damage in isolation. However, experimental (23,47) and epi-
demiologic (48) evidence indicates that smoking and choles-
terol levels may be importantly linked. Apart from encouraging
smokers to quit, a combination of L-arginine, antioxidant and
cholesterol-lowering therapy might therefore act synergistically
to maximize NO bioavailability.
Diabetes. Of the three risk factors studied, IDDM appears
to be the worst, with no improvement in FMD after L-arginine
infusion. This finding is in accord with its known adverse
impact on early arterial injury and cardiovascular mortality (3).
Although reduced FMD and impaired response to GTN have
been reported previously, both by us and other workers
(27,49), there is not yet a consensus on these findings (50).
These effects complicate the interpretation of the nature of
vascular injury and may reflect reduced smooth muscle re-
sponses to local NO or abnormalities in the vessel wall matrix
itself. An additional element to vascular damage is therefore
Figure 3. GTN-induced dilation in the four subject groups. In the
hypercholesterolemic subjects and smokers, GTN-induced dilation was
not significantly different than that in control subjects but was signifi-
cantly reduced in diabetic subjects (p 5 0.026). Bold lines represent
mean values.
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likely to be present in IDDM, and hyperglycemia-related
oxidant stress may be an important factor. Autooxidation of
glucose, stimulation of the polyol pathway and the formation
of advanced glycosylation end products all increase oxidant
stress in diabetes, and the effect is compounded by the reduced
levels of antioxidants that occur in diabetes (6,51,52). There is
also evidence of a failure to regulate intracellular arginine
levels in diabetes (53). It is therefore not surprising that the
diabetic group showed no improvement in vascular reactivity
with L-arginine. Our previous work has shown that plasma
LDL and FMD are related in IDDM (27). An aggressive
approach to other additional risk factors may thus be beneficial
in IDDM, although the incremental benefit that L-arginine
may have in addition to lipid-lowering and antioxidant therapy
is unknown (54). Further studies are needed to assess both
their roles and those of competitive inhibitors such as ADMA
in the differing perturbations of NO synthase in the different
risk factor groups.
Conclusions. We showed that the endothelial dysfunction
characteristic of young people with different cardiovascular
risk factors may differ in its pathophysiology, and this differ-
ence is presumably responsible for the distinct vascular re-
sponses observed in response to the short-term administration
of L-arginine in the diabetic cohort. Interventions to alter the
natural history of atherogenesis are likely to be most effective
early in young people, when intuitively arterial damage is more
likely to be reversible. The information from the present study
will help to design therapeutic strategies appropriate to differ-
ent cardiovascular risk factors, and to optimize endothelial
protection, multifactorial approaches are likely to be needed.
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